Search

Your search keyword '"Shao, Liyang"' showing total 342 results
Start Over Author "Shao, Liyang"
342 results on '"Shao, Liyang"'

105. An Ultrawideband Three-Dimensional Bandpass Frequency Selective Surface.

Author

Jiang, Xiaonan, Rashid, Amir Khurrum, Xu, Wentao, Cheng, Qiang, Shao, Liyang, and Zhang, Qingfeng

Abstract

A new ultrawideband frequency selective surface(FSS) is proposed, which exhibits six resonances to achieve a flat passband. It consists of a three-dimensional (3-D) configuration. However, unlike many other 3-D FSSs, the proposed structure can be assembled through simple steps involving single-layer printed circuit board (PCB) fabrication only. Its unit-cell consists of a wire-loop conducting pattern, printed on a dielectric substrate. The pattern excites four resonances while two resonances are contributed by the dielectric. These six resonances are properly tuned and coupled to form an ultrawide frequency band from 7.53 to 29.45 GHz. It translates to a $-$ 3 dB bandwidth of 119 $\%$. Our design guidelines and discussions are validated through both simulation and measurement results. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

120. Photonic hooks from Janus microcylinders

Author

Gu, Guoqiang, primary, Shao, Liyang, additional, Song, Jun, additional, Qu, Junle, additional, Zheng, Kai, additional, Shen, Xingliang, additional, Peng, Zeng, additional, Hu, Jie, additional, Chen, Xiaolong, additional, Chen, Ming, additional, and Wu, Qiang, additional

Published
2019
Full Text
View/download PDF

121. Ultrasensitive biosensor based on magnetic microspheres enhanced microfiber interferometer

Author

Kumar, Rahul, primary, Leng, Yuankui, additional, Liu, Bin, additional, Zhou, Jun, additional, Shao, Liyang, additional, Yuan, Jinhui, additional, Fan, Xinyu, additional, Wan, Shengpeng, additional, Wu, Tao, additional, Liu, Juan, additional, Binns, Richard, additional, Fu, Yong Qing, additional, Ng, Wai Pang, additional, Farrell, Gerald, additional, Semenova, Yuliya, additional, Xu, Hengyi, additional, Xiong, Yonghua, additional, He, Xingdao, additional, and Wu, Qiang, additional

Published
2019
Full Text
View/download PDF

128. Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes: results from a phase 3, randomized, double-blind, placebo-controlled trial.

Author

Worm, Margitta, Simpson, Eric L., Honari, Golara, Soong, Weily, Pinter, Andreas, Masuda, Koji, Shao, Liyang, Dubost-Brama, Ariane, Bansal, Ashish, Korotzer, Andrew, and Rossi, Ana B.

Subjects
SKIN inflammation, DUPILUMAB, ATOPIC dermatitis, ATOPY, IMMUNOGLOBULIN A, PATIENT safety, ECZEMA
Abstract

Introduction/Background Dupilumab has previously shown to significantly improve signs, symptoms, and quality of life in patients with moderate-to-severe atopic hand and foot dermatitis. Objective To investigate the efficacy of dupilumab across morphological subtypes in patients with moderate-to-severe atopic hand and foot dermatitis. Methods: The phase 3, randomized, double-blind LIBERTY-AD-HAFT (NCT04417894) trial enrolled patients aged =12 years with moderate-to-severe (Investigator's Global Assessment [IGA] score of 3/4) atopic hand and foot dermatitis. Patients were randomized to dupilumab monotherapy 300 mg every 2 weeks (q2w) in adults; 200/300 mg q2w in adolescents, or placebo for 16 weeks. This analysis reports the percent change from baseline in modified total lesion sign score (mTLSS) by hand and foot morphological subtypes: chronic dry fissured, hyperkeratotic (palmar/plantar), and other. Results: 133 patients enrolled into this study and were randomized to dupilumab (n = 67) or placebo (n = 66). Atopic hand and foot morphologies were reported in 3 categories: chronic dry fissured (n = 63), hyperkeratotic (palmar/plantar; n = 37), and other (n = 33) In the "other" category, dyshidrotic was the most frequent morphology (n = 13). mTLSS values were similar at baseline for all morphological subtypes. At Week 16, greater improvements were seen in the percent change from baseline (SE) in mTLSS for patients receiving dupilumab vs placebo in all categories: chronic dry fissured (-65.6% [5.1] vs -31.5% [6.2]), hyperkeratotic (palmar/plantar; -58.2% [7.6] vs -11.8% [7.7]), and other (-64.5% [11.6] vs -29.9% [9.0]). Safety was consistent with the known dupilumab safety profile in patients with atopic dermatitis. Conclusions: The efficacy of dupilumab remains consistent across different hand and foot dermatitis morphologies and shows higher treatment benefit across subtypes compared with placebo. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results